CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant ...
The MarketWatch News Department was not involved in the creation of this content. -- CANDID-CNS(TM) is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback